Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II 177Lu-DOTATATE for relapsed or refractory high-risk neuroblastoma in children
NL-OMON51935Phase 2Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Feb 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in neuroblastoma, sponsored by Karolinska University Hospital. Primary endpoint: Primary response assessment. Started Feb 2023; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON51935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51935.